A device for in-vitro modelling in-vivo tissues of organs that includes a first body portion with at least one access chamber, a second body portion with at least one culturing chamber, and a culturing membrane dividing the at least one access chamber from the culturing chamber. The device further includes a third body portion with at least one actuation chamber having at least one limitation cavity, and an actuation membrane dividing the at least one culturing chamber from the at least one actuation chamber. With the device, a robust actuation system can be provided that does not depend on the mechanical properties of the actuation membrane material, nor on the pressure, and that allows to mimic three-dimensional deformations of the tissue, in particular of lung alveoli.

Provided are a method for producing a cell tissue, including a culturing step of culturing cells capable of serving as a feeder inside opening pores and communicating pores of a porous film having a plurality of the opening pores provided on a surface thereof and the communicating pores communicating mutually adjacent opening pores with one another; and a porous film including a plurality of opening pores provided on a surface thereof and communicating pores communicating mutually adjacent opening pores with one another.

An incubation chamber that may be provided in modular form in order to provide flexibility in flow rate and/or residence time of a product stream is disclosed. Assemblies including such incubation chambers for purification of biomolecules are also disclosed, as are methods for biomolecule purification, and in particular, methods for virus inactivation in an incubation chamber or in a plurality of incubation chambers arranged in series.

A biological tissue forming device that ensures a cell-cell interaction and an exchange of liquid components between cell layers of a formed biological tissues with high efficiency can be provided. A biological tissue forming device for forming a biological tissue having a plurality of cell layers formed of adherent cells has both surfaces on which culture regions of the adherent cells are disposed, and includes a culture membrane arranged between the plurality of cell layers after the adherent cells are cultured and a plurality of flow passages divided by the culture membrane. The culture membrane is formed of a readily-soluble material.

Cartridges for manufacturing a population of cells suitable for formulation as a cellular therapeutic are disclosed herein, along with systems and instruments for operating the cartridges and performing methods to generate the population of cells suitable for formulation as a cellular therapeutic. The population of cells suitable for formulation as a cellular therapeutic can be immunological cells, such as T lymphocytes, including endogenous T cells (ETCs), tumor infiltrating lymphocytes (TILs), CAR T-cells, TCR engineered T-cells, or otherwise engineered T-cells. The systems and methods can be largely automated.

A platform for testing cell response to biochemical agents. The TrophoWell™ includes a well which contains a gel, and a plurality of capillaries that open into it. Cells and various biochemical agents such as drugs and growth factors are flown through those capillaries. The platform allows for the evaluation of cell response by imaging. The platform is a cost effective testing platform and can be used in the fields for drug discovery and personalized medicine.

Provided herein are devices and methods that enable co-incubation of microorganisms. Also provided are methods of making such devices for co-incubation of microorganisms, and various applications of such devices.

The invention relates to a human in vitro model and a method of constructing the same to mimic the alveolar region of the airways to assess the respiratory toxicology and/or physiological and/or biological response of inhaled products, chemicals and particles. There is provided a three-dimensional in vitro alveolar lung model and a method of constructing the same comprising a culture well provided with a membrane configured to separate the culture well into a first compartment and a second compartment, wherein the membrane has first side configured form a wall of the first compartment and a second side configured to form a wall of the second compartment, wherein alveolar type I epithelial cells are provided in the first compartment and alveolar macrophage-like cells are provided in the second compartment.

This invention consists of a method for the development of personalized target anticancer therapies based on aptamers and through the systemic modeling of an individual in microfluidic devices. This invention is embodied in microfluidic devices, connections, systems, and methods for the development specific aptamers for the relevant complex biological environment targets. In a first mode, the invention provides methods for the development of target therapies which involves the maintenance of target cancerous cells in co-culture with non-target and non-cancerous cells by using microfluidic devices modularly arranged in closed systems for the development of aptamers. In a second mode, the invention provides a method for the development of target therapies, which includes the maintenance of target cells in co-culture with non-target cells by using microfluidic devices modularly arranged in closed systems. In this case, the invention provides the development of aptamers for the relevant target in homeostatic balance with the components of the fluid conditioned by the co-culture with non-target cells.

The present invention provides compositions, systems, kits, and methods for combining a. single myeloma cell and a single B-cell (e.g., from an animal exposed to a desired antigen) via discrete entity (e.g., droplet) microfluidics. In certain embodiments, a microfluidic device is used to merge a discrete entity containing a B-cell, and a discrete entity containing a myeloma cell, and a discrete entity containing gellable material, at a merger region via a trapping element in order to generate a combined discrete entity. In further embodiments, the combined discrete entity is treated such that a gelled discrete entity is formed.